关于公司股东减持股份的预披露公告 公司股东南京诺维科思创业投资合伙企业（有限合伙）保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 | 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-044 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 南京药石科技股份有限公司（以下简称"公司"）员工持股平台南京诺维科思创业 投资合伙企业（有限合伙）持有公司股份5,404,744股，占剔除已回购股份后总股本比 例2.7174%，计划在本减持计划预披露公告之日起十五个交易日后的三个月内（窗口期 不减持），以集中竞价、大宗交易方式减持其持有的全部公司股份。其中，通过集中竞 价交易方式减持的，在任意连续90个自然日内减持股份数量不超过公司股份总数的 1.00%；通过大宗交易方式减持的，在任意连续90个自然日内减持股份数量不超过公司 股份总数的2.00%（减持期间如公司有送股、资本公积金转增股本等导致持股数量变化， ...

Group 1: Company Performance and Capacity Utilization - The company's production capacity utilization rate is stable at 60%-70%, which is considered reasonable within the industry [2] - The newly constructed 503 workshop is in the initial production phase, with capacity utilization currently on the rise [2] - The company has over 70 clinical phase III and commercialization projects, with new orders continuing to grow, where overseas orders account for 60-70% and domestic orders for 30-40% [2] Group 2: Product Development and Market Strategy - There is a significant increase in demand for innovative molecular building blocks due to trends in drug development [4] - The company collaborates with Alipheron to create a large compound library, enhancing the drug development process for clients [4] - In 2025, the company is optimizing its CDMO business strategy by establishing a sales team in Europe and enhancing local service capabilities in North America [5] Group 3: Competitive Positioning and Industry Trends - The company aims to strengthen its core competitiveness by focusing on quality delivery, green technology, and foundational innovation [6] - The CDMO industry faces structural contradictions, with a surplus of low-quality capacity and a scarcity of high-compliance capacity [6] - The company has been recognized for its quality management system, achieving international standards through rigorous audits [6] Group 4: Inventory Management and Financial Health - The company has recognized an inventory impairment loss of 59.87 million yuan due to market price fluctuations [8] - The increase in inventory is attributed to the need for a variety of molecular building blocks during drug research and development [7] - The company implements strict inventory impairment policies and conducts regular assessments to mitigate risks [8]

| 证券代码：300725 | 证券简称：药石科技 | 公告编号：2025-043 | | --- | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | | 南京药石科技股份有限公司 关于公司董事减持股份的预披露公告 公司董事陈谌保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 2、本次拟减持的股份来源：2019年限制性股票股权激励股份以及实施权益分派送 转的股份。 南京药石科技股份有限公司（以下简称"公司"）董事陈谌女士持有公司股份5.46 万股，占剔除已回购股份后总股本比例0.0275%，计划在本减持计划预披露公告之日起 十五个交易日后的三个月内（窗口期不减持），以集中竞价方式减持公司股份不超过1.3 万股（占剔除已回购股份后总股本比例0.0065%）。 公司于近日收到公司董事陈谌女士的《股份减持计划告知函》，现将有关情况公 告如下： | 姓名 | 职务 | 持股数量 | 占剔除已回 | 本次拟减持 | 占剔除已回 | | --- | --- | --- | -- ...

根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 15 号——可转换公司债券》等有关规定，南京药石科技股份有限 公司（以下简称"公司"）现将 2025 年第二季度可转换公司债券转股及公司股份 变动情况公告如下： | 证券代码：300725 | 证券简称：药石科技 公告编号：2025-042 | | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | 南京药石科技股份有限公司 关于 2025 年第二季度可转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、"药石转债"（债券代码：123145）转股期为 2022 年 10 月 26 日至 2028 年 4 月 19 日；最新有效的转股价格为 33.61 元/股。 2、2025 年第二季度，共有 240 张"药石转债"完成转股（票面金额共计 24,000.00 元人民币），合计转成 699 股"药石科技"股票（股票代码：300725）。 3、截至 2025 年第二季度末，公司剩余可转债为 11,471,648 张，剩余可转债 ...

Core Insights - The dialogue at the CPHI China exhibition highlighted the green transformation of the CDMO industry in China, emphasizing the shift from "manufacturing" to "intelligent manufacturing" through technological innovation and cost efficiency [1][3]. Group 1: Technological Innovations - Dr. Yang Minmin discussed the challenges of safety and environmental risks in the organic chemistry industry, leading to the exploration of new technologies like continuous flow and micro-packed bed [3]. - Drug Stone Technology has applied micro-packed bed technology in hydrogenation reactions for over a decade, enhancing selectivity and addressing the complexity of traditional process approvals [3]. - The company has accumulated experience in over 50 continuous flow technology projects, with more than 30% of R&D projects utilizing this technology, resulting in improved production efficiency and cost reduction [3]. Group 2: Cost and Efficiency Dynamics - Dr. Chen Zhihong highlighted that the continuous flow technology reduced the production cycle of drug intermediates from 40 days to 10 days, decreasing the footprint by 95% and solvent usage by over 50% [4]. - Over 60% of Drug Stone's Building Block business and 30%-40% of its CDMO business leverage new technologies, creating a positive cycle through standardized reactions that lower equipment costs [4]. - The Chinese pharmaceutical industry is projected to have an API export value of nearly $50 billion in 2024, facing pressures from domestic competition and carbon tariffs from Europe and the U.S. [4]. Group 3: Global Competitiveness and Challenges - Dr. Zhang Yantao noted that the focus of the industry has shifted from hardware construction to process management, reflecting improvements in green manufacturing capabilities [5]. - Drug Stone's overseas strategy involves a "local R&D + global delivery" model based on continuous flow technology, significantly reducing labor requirements and overcoming cost and environmental challenges in Europe and the U.S. [5]. - The total value of innovative drug license outs in China is expected to reach approximately $50 billion in 2024, urging Chinese CDMOs to accelerate their global expansion [5]. Group 4: Industry Insights and Future Vision - Dr. Yang Minmin envisioned transforming fine chemical plants into intelligent office environments, indicating a shift in industry paradigms [6]. - Dr. Zhang Yantao emphasized that advanced manufacturing technologies will inevitably take root in the largest manufacturing countries [6]. - The dialogue underscored the importance of embedding sustainability throughout the product development lifecycle to enhance business communication and competitiveness in the global pharmaceutical landscape [6].

Group 1 - The smart medical sector is experiencing a significant upward trend, with notable stock price increases for several companies [1] - Jincheng Pharmaceutical (300233) has seen its stock rise by over 10% [1] - Heertai (002402) and Weining Health (300253) have both increased by over 9% [1] - Yaoshi Technology (300725) has experienced a stock price increase of over 5% [1] - Other companies such as Yuandong Biology and Chengdu Xian Dao are also showing upward movement [1]

南京药石科技股份有限公司相关 债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【314】号 02 信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经授权 ...

| 证券代码：300725 | 证券简称：药石科技 公告编号：2025-041 | | --- | --- | | 债券代码：123145 | 债券简称：药石转债 | 南京药石科技股份有限公司 关于参股公司在香港联交所主板挂牌上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 参股公司上市情况概述 根据《企业会计准则》相关规定，公司对所持药捷安康的股权划分为"以公 允价值计量且其变动计入其他综合收益的金融资产"，并列报在"其他权益工具 投资"。药捷安康上市后，公司对其会计核算方法不会发生变化，对本公司财务 状况的实际影响最终以审计报告为准。敬请广大投资者注意投资风险。 特此公告。 南京药石科技股份有限公司董事会 2025年6月23日 南京药石科技股份有限公司（简称"本公司"或"公司"）参股公司药捷安 康(南京)科技股份有限公司（简称"药捷安康"）于2025年6月23日在香港联合 交易所有限公司（简称"香港联交所"）主板挂牌上市，股份代号02617，药捷 安康本次公开发行新股15,281,000股，发行价格为13.15港元/股。药捷安康在香 港上市 ...

Group 1 - The company, Nanjing Pharmablock Sciences Co., Ltd., issued convertible bonds to unspecified investors, with a total issuance of 11.5 million bonds at a face value of 100 RMB each, raising a total of 1.15 billion RMB [3][5][23] - The net proceeds from the bond issuance, after deducting various fees, amounted to approximately 1.14 billion RMB [3][23] - The bonds are set to mature in six years, with an annual interest rate that increases progressively from 0.3% in the first year to 2.0% in the sixth year [5][6] Group 2 - In 2024, the company reported a revenue of 1.688 billion RMB, a decrease of 2.12% year-on-year, while the net profit attributable to shareholders increased by 11.24% to 220 million RMB [21][22] - The company achieved a net cash flow from operating activities of 303 million RMB, reflecting a 22.68% increase compared to 2023 [21][22] - The company’s new orders in the CDMO segment grew by 12.43% year-on-year, with a 31.12% increase in order quantity [21][22] Group 3 - The initial conversion price for the bonds was set at 92.98 RMB per share, with subsequent adjustments based on stock performance and dividend distributions [8][29] - The bond's credit rating has been maintained at AA, with a stable outlook as per the annual tracking reports [18][26] - The company has implemented measures to manage customer credit and optimize cash flow, contributing to improved financial performance [21][22]

受托管理事务报告 （2024 年度） 股票简称：药石科技 股票代码：300725 转债简称：药石转债 转债代码：123145 南京药石科技股份有限公司 向不特定对象发行可转换公司债券 债券受托管理人 （深圳市前海深港合作区南山街道桂湾五路128号前海深港基金小镇B7栋401） 二〇二五年六月 重要声明 本报告依据《可转换公司债券管理办法》（以下简称"管理办法"）、《南京药 石科技股份有限公司与华泰联合证券有限责任公司关于南京药石科技股份有限 公司向不特定对象发行可转换公司债券之债券受托管理协议》（以下简称"受托 管理协议"）、《南京药石科技股份有限公司向不特定对象发行可转换公司债券并 在创业板上市募集说明书》（以下简称"募集说明书"）、《南京药石科技股份有限 公司 2024 年年度报告》等相关公开信息披露文件、第三方中介机构出具的专业 意见等，由本期可转换公司债券受托管理人华泰联合证券有限责任公司（以下简 称"华泰联合证券"）编制。华泰联合证券对本报告中所包含的从上述文件中引 述内容和信息未进行独立验证，也不就该等引述内容和信息的真实性、准确性和 完整性做出任何保证或承担任何责任。 本报告不构成对投资者进行或 ...